| Joel Latimer, MFT | |
|
9961 Sierra Ave, Fontana, CA 92335-6720 | |
| (909) 427-3910 | |
| Not Available |
| Full Name | Joel Latimer |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 9961 Sierra Ave, Fontana, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063616118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | MFC39907 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joel Latimer, MFT 9961 Sierra Ave, Fontana, CA 92335-6720 Ph: (909) 427-3910 | Joel Latimer, MFT 9961 Sierra Ave, Fontana, CA 92335-6720 Ph: (909) 427-3910 |
News Archive
Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing.
Understanding how gastric bypass surgery changes the properties of nerve cells that help regulate the digestive system could lead to new treatments that produce the same results without surgery, according to Penn State College of Medicine scientists, who have shown how surgery restores some properties of nerve cells that tell people their stomachs are full.
Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.
› Verified 8 days ago
Anh Thuc Ly, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 9985 Sierra Ave # Mob4, Fontana, CA 92335 Phone: 909-427-5191 | |
Diana Perez Duran, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-997-2645 | |
Ms. Monica Victoria Pulido, MSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 8485 Tamarind Ave, Fontana, CA 92335 Phone: 909-428-2366 | |
Monique Bautista, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 6101 Cherry Ave, Fontana, CA 92336 Phone: 909-202-8361 | |
Ms. Rachel Michelle Estrada, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 7525 Wynstone Pl, Fontana, CA 92336 Phone: 951-218-2882 | |
Felipe Amaya, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6060 Firestone Dr, Fontana, CA 92336 Phone: 909-549-3950 |